Fundamental Analysis (Long term)

How to Analyze Stocks – 6-Step Framework (Inspired by Peter Lynch):

1️⃣ Understand the Business – What do they do? Simple explanation?

2️⃣ Industry & Moat – Competitors? Pricing power? Can it be copied?

3️⃣ Financials Deep Dive – Debt? Liquidity? Profit growth? Cash flow?

4️⃣ Growth Potential – Future plans? Earnings growth 15%+?

5️⃣ Valuation – P/E reasonable? PEG? Undervalued?

6️⃣ Insider Behavior – Promoters buying? Insider purchases?

ROE Myths Exposed: Why 35% Isn't Always Great

Beginners chase high ROE companies thinking they're goldmines. ROE deception comes in 4 forms that inflate numbers without real strength.

ROE Formula
Net Profit ÷ Shareholders' Equity. For ₹100 equity, how much profit? Clean math, dirty tricks.

4 ROE Inflators

1. Heavy Debt
- A: ₹100 profit, ₹500 equity, ₹0 debt → 20% ROE
- B: ₹100 profit, ₹200 equity, ₹800 debt → 50% ROE
Same profit. B risks bankruptcy for screen appeal.

2. Buybacks/Past Losses
Share repurchases or accumulated losses shrink equity base. ROE jumps automatically—no business improvement.

3. One-Year Profit Spike
Land sale spikes profit temporarily. ROE shines one year, normalizes next. Cyclical trap.

4. Non-Operating Income
Asset sales, forex gains, tax reversals boost profit. Check operating cash flow to validate.

True Quality Checks
- ROCE (EBIT ÷ Equity+Debt): Exposes debt reliance (high ROE, low ROCE = red flag)
- ROE Consistency: 5-10 years proves sustainability
- Debt/Equity <1: High leverage + high ROE = danger
- Steady Revenue/Profit Growth: Avoid lumpy earnings

Real Examples
Asian Paints, HDFC Bank (pre-merger): 20-25% ROE for 10+ years. Low debt, operational compounding.

Core Lesson
Flashy ROE hides weak businesses. Boring, consistent quality creates wealth. Understanding protects capital.

@Stockupdate9

Earkart Ltd Hearing Aids (MCap Rs 165 Cr)

Market Opportunity
- India penetration: 1% vs China 8%, US/EU 35%
- 5-10% upside = 5-10x market

Supply Gap
- Only 7k audiologists (metro-focused)

Tech Edge
- Remote audiometry via ENT clinic devices

Manufacturing
- India-made aids; 2L annual capacity
- Pricing: <Rs 1L vs imports Rs 3-5L

Growth Thesis
- Ageing population + awareness
- 5yr revenue target: Rs 300 Cr

Key Takeaway
Underpenetrated mkt + remote tech = multi-bagger potential

India’s Semiconductor Readiness:
The Four Pillars

IPCA Laboratories — Strategy & Growth Update

Unichem Integration
- EBITDA margin expansion target: +12% in 2–3 years
- Revenue growth: 10–12% post market share recovery
- US business target: ₹100 Cr via Unichem channel

US & Global Filings
- 5–6 new US filings annually via own APIs
- 30+ pending approvals over next 5 years
- Europe filings initiated — reduce 70% US dependency

R&D Ramp-Up
- Spend rising: 3.25% → 4.5% of sales
- Biosimilar trials commencing
- GLP opportunity via in-licensing under evaluation
- E.coli R&D facility under development

Near-Term Headwinds
- Contract mfg. margin pressure: 1–2 more quarters
- API pricing stable | growth guided at 6–7%

FY26 Guidance
- Revenue growth: 8–10%
- EBITDA margin: +1% → ~20%

Key Takeaway
- Unichem = core re-rating trigger
- 30+ US approvals = multi-year revenue visibility
- Biosimilar & specialty = long-term growth engine
- Near-term pain — structural story intact